Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients

por Saygin, Caner, Cannova, Joseph, Stock, Wendy, Muffly, Lori
Publicado 2022

Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents

por Maristany, Sumiko, DuVall, Adam S., Stock, Wendy, Adeleye, Amanda J.
Publicado 2022

D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia

por Anderson, Daniela R., Stock, Wendy, Karrison, Theodore G., Leader, Avi
Publicado 2022

Impact of Treatment Site on Disparities in Outcome among Adolescent and Young Adults with Hodgkin Lymphoma

por Wolfson, Julie, Sun, Can-Lan, Wyatt, Laura, Stock, Wendy, Bhatia, Smita
Publicado 2017

Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acu...

por Wu, Sharon, Wang, Mengxi, Alqahtani, Amani, Lou, Mimi, Stock, Wendy, Bhojwani, Deepa, Alachkar, Houda
Publicado 2022

2193: Targeting MELK in acute lymphoblastic leukemia, new therapeutic approach

por Alachkar, Houda, Mutonga, Martin, de Albuquerque, Amanda, Deo, Rucha, Malnassy, Gregory, Nakamura, Yusuke, Stock, Wendy
Publicado 2018

Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials

por Hantel, Andrew, Luskin, Marlise R., Garcia, Jacqueline S., Stock, Wendy, DeAngelo, Daniel J., Abel, Gregory A.
Publicado 2021

Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL)()

por Mutonga, Martin, Tamura, Kenji, Malnassy, Gregory, Fulton, Noreen, de Albuquerque, Amanda, Hamamoto, Ryuji, Stock, Wendy, Nakamura, Yusuke, Alachkar, Houda
Publicado 2015

Influence of participant and reviewer characteristics in application scores for a hematology research training program

por Vesely, Sara K., King, Allison, Vettese, Emily, Heller, John G., Cuker, Adam, Calhoun, Cecelia, Stock, Wendy, Homer, Morgan, Fritz, Josel, Sung, Lillian
Publicado 2023

Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy

por Liang, Guanghao, Wang, Linchen, You, Qiancheng, Cahill, Kirk, Chen, Chuanyuan, Zhang, Wei, Fulton, Noreen, Stock, Wendy, Odenike, Olatoyosi, He, Chuan, Han, Dali
Publicado 2023

Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia

por Alachkar, Houda, Fulton, Noreen, Sanford, Ben, Malnassy, Greg, Mutonga, Martin, Larson, Richard A., Bloomfield, Clara D., Marcucci, Guido, Nakamura, Yusuke, Stock, Wendy
Publicado 2016

Management of important adverse events associated with inotuzumab ozogamicin: expert panel review

por Kebriaei, Partow, Cutler, Corey, de Lima, Marcos, Giralt, Sergio, Lee, Stephanie J., Marks, David, Merchant, Akil, Stock, Wendy, van Besien, Koen, Stelljes, Matthias
Publicado 2018

Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation se...

por Balagopal, Vidya, Hantel, Andrew, Kadri, Sabah, Steinhardt, George, Zhen, Chao Jie, Kang, Wenjun, Wanjari, Pankhuri, Ritterhouse, Lauren L., Stock, Wendy, Segal, Jeremy P.
Publicado 2019

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia

por Eisfelder, Bartholomew J., Saygin, Caner, Wynne, Joseph, Colton, Margaret W., Fischietti, Mariafausta, Beauchamp, Elspeth M., Cheng, Jason X., Odenike, Olatoyosi, Roboz, Gail, Alachkar, Houda, Stock, Wendy
Publicado 2021

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia

por Alachkar, Houda, Mutonga, Martin B.G., Metzeler, Klaus H., Fulton, Noreen, Malnassy, Gregory, Herold, Tobias, Spiekermann, Karsten, Bohlander, Stefan K., Hiddemann, Wolfgang, Matsuo, Yo, Stock, Wendy, Nakamura, Yusuke
Publicado 2014

Next generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma

por Li, Zejuan, Stölzel, Friedrich, Onel, Kenan, Sukhanova, Madina, Mirza, M. Kamran, Yap, Kai Lee, Borinets, Olesya, Larson, Richard A., Stock, Wendy, Sasaki, Mark M., Joseph, Loren, Raca, Gordana
Publicado 2015

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia

por Liu, Hongtao, Zha, Yuanyuan, Choudhury, Noura, Malnassy, Gregory, Fulton, Noreen, Green, Margaret, Park, Jae-Hyun, Nakamura, Yusuke, Larson, Richard A., Salazar, Andres M., Odenike, Olatoyosi, Gajewski, Thomas F., Stock, Wendy
Publicado 2018

T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia

por Alachkar, Houda, Mutonga, Martin, Malnassy, Gregory, Park, Jae-Hyun, Fulton, Noreen, Woods, Alex, Meng, Liping, Kline, Justin, Raca, Gordana, Odenike, Olatoyosi, Takamatsu, Naofumi, Miyamoto, Takashi, Matsuo, Yo, Stock, Wendy, Nakamura, Yusuke
Publicado 2015

Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the firs...

por Fan, Yun, Artz, Andrew S., van Besien, Koen, Stock, Wendy, Larson, Richard A., Odenike, Olatoyosi, Godley, Lucy A., Kline, Justin, Cunningham, John M., LaBelle, James L., Bishop, Michael R., Liu, Hongtao
Publicado 2019

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO...

por Kantarjian, Hagop M., DeAngelo, Daniel J., Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, O’Brien, Susan M., Jabbour, Elias, Wang, Tao, Liang White, Jane, Sleight, Barbara, Vandendries, Erik, Advani, Anjali S.
Publicado 2019